Pediatrix Medical Group (MD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
Annual meeting scheduled for May 7, 2026, to be held virtually for shareholders of record as of March 9, 2026.
Shareholders are encouraged to review proxy materials online and may request paper copies by April 27, 2026.
Voting matters and shareholder proposals
Election of nine directors for terms expiring at the next annual meeting or until successors are elected.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2026.
Advisory vote on executive compensation for the 2025 fiscal year.
Approval of the Second Amended and Restated 2008 Incentive Compensation Plan.
Consideration of other business that may properly come before the meeting.
Board of directors and corporate governance
Nine director nominees listed, including Laura A. Linynsky, Thomas A. McEachin, Kurt D. Newman, M.D., Mark S. Ordan, Michael A. Rucker, Guy P. Sansone, John M. Starcher, Jr., Shirley A. Weis, and Sylvia J. Young.
Latest events from Pediatrix Medical Group
- Proxy covers director elections, auditor ratification, pay, and incentive plan approval.MD
Proxy filing27 Mar 2026 - Q4 2025 delivered strong EBITDA and net income, with 2026 EBITDA growth projected at 5%.MD
Q4 202519 Feb 2026 - Q2 net loss from impairments; restructuring and new leadership target $30M EBITDA boost.MD
Q2 20242 Feb 2026 - Refocusing on core hospital-based care, with stable demand and growth in maternal-fetal medicine.MD
Jefferies Global Healthcare Conference1 Feb 2026 - Q3 revenue up 0.9%, Adjusted EBITDA rises, but impairments drive a nine-month net loss.MD
Q3 202417 Jan 2026 - Q4 2024 showed robust results and a prudent 2025 outlook after portfolio restructuring.MD
Q4 202423 Dec 2025 - Board recommends approval of all proposals, with a focus on performance-based executive pay and governance.MD
Proxy Filing2 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve executive pay on May 8, 2025.MD
Proxy Filing2 Dec 2025 - Q1 net income rose to $20.7M, Adjusted EBITDA hit $49.2M, and guidance was raised.MD
Q1 202525 Nov 2025